Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

Hye Won Lee, Seungup Kim, Oidov Baatarkhuu, Junyong Park, doyoung kim, SangHoon Ahn, KwangHyub Han, Beom Kyung Kim

Research output: Contribution to journalShort survey

Abstract

Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.

Original languageEnglish
JournalClinical Gastroenterology and Hepatology
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Hepatitis B
Infection
Serum
DNA
Alanine Transaminase
Hepatocellular Carcinoma
Fibrosis

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{940eb265beaf4a1c88f12b603c7881c0,
title = "Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection",
abstract = "Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.",
author = "Lee, {Hye Won} and Seungup Kim and Oidov Baatarkhuu and Junyong Park and doyoung kim and SangHoon Ahn and KwangHyub Han and Kim, {Beom Kyung}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cgh.2019.01.002",
language = "English",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

AU - Lee, Hye Won

AU - Kim, Seungup

AU - Baatarkhuu, Oidov

AU - Park, Junyong

AU - kim, doyoung

AU - Ahn, SangHoon

AU - Han, KwangHyub

AU - Kim, Beom Kyung

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.

AB - Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85069514951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069514951&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2019.01.002

DO - 10.1016/j.cgh.2019.01.002

M3 - Short survey

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

ER -